Prevention and treatment of diabetic nephropathy

Patent metadata

Field	Value
Publication number	US-12097172-B2
Application number	US-202217679842-A
Country	US
Kind code	B2
Filing date	Feb 24, 2022
Priority date	Oct 3, 2016
Publication date	Sep 24, 2024
Grant date	Sep 24, 2024

Abstract

Embodiments herein disclose methods relating to diabetic nephropathy (DN); methods for preventing the onset and also for preventing the progressing of DN, as well as the treatment of DN in diabetic subjects comprising administering reparixin and/or ladarixin which are inhibitors of CXCL8 receptor CXCR1 and CXCR2 activation.

First claim

What is claimed is:

1. A method of preventing the onset of diabetic nephropathy or the progression of diabetic nephropathy (DN) in a subject in need thereof comprising administering a CXCR1 and/or CXCR2 inhibitor to the subject who has been diagnosed with diabetes and microalbuminuria.

2. The method of claim 1 , wherein the CXCR1 and/or CXCR2 inhibitor is a compound selected from the group consisting of R(-)-2[(4-isobutylphenyl)propionyl]-methanesulfonamide, R(-)-2[(4′-trifluoromethane sulfonyloxy)phenyl]-N-methanesulfonyl propionamide and (2S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl] amino}phenyl) propionic acid and salts thereof.

3. The method of claim 1 , wherein the CXCR1 and/or CXCR2 inhibitor is a compound selected from the group consisting of the lysine salt of R(-)-2[(4-isobutylphenyl)propionyl]-methanesulfonamide, the sodium salt of R(-)-2[(4′-trifluoromethane sulfonyloxy)phenyl]-N-methanesulfonyl propionamide, and the sodium salt of 2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl] amino}phenyl) propionic acid.

4. The method of claim 1 , wherein the diabetes is Type 1 diabetes (T1D) or Type 2 diabetes (T2D).

5. The method of claim 1 , wherein the subject has at least one of the following single nucleotide polymorphisms at the CXCR1 locus: s13006838, rs4674308; rs4674309; rs3755042; rs7601872; and rs664514.

6. The method of claim 1 , further comprising measuring the protein level in a sample of urine from the subject.

7. The method of claim 6 , wherein the subject has been determined to have rate of excretion of albumin between 30 mg and 300 mg per day.

8. The method of claim 6 , further comprising comparing the measured urine protein level with a urine protein reference, wherein the urine protein reference is the level of protein in urine samples obtained in normal healthy subjects that do not have any nephropathy.

9. The method of claim 1 , further comprising measuring the IL8 level in a sample obtained from the subject.

10. The method of claim 9 , wherein the subject has been determined to have a urinary level of IL8 higher than 2.41 pg/ml.

11. The method of claim 9 , wherein in the sample is a urine sample, kidney biopsy, a serum sample, a blood sample, or a plasma sample.

12. The method of claim 10 , further comprising comparing the measured IL8 level with an IL8 reference, wherein the IL8 reference is the IL8 level in the respective samples obtained in normal healthy subjects that do not have any nephropathy.

13. The method of claim 1 , wherein the CXCR1 and/or CXCR2 inhibitor is administered to the subject prior to, simultaneously or sequentially with the administration of at least one other therapy for diabetes, metabolic syndrome, cardiovascular disease or high blood pressure.

14. The method of claim 1 , wherein the CXCR1 and/or CXCR2 inhibitor is administered with at least one active molecule used to treat diabetes.

15. The method of claim 1 , wherein the CXCR1 and/or CXCR2 inhibitor is in a composition formulated for delivery to the kidney.

16. The method of claim 1 , wherein the CXCR1 and/or CXCR2 inhibitor is administered by a systemic route, an enteral route, or a parenteral route.

17. The method of claim 1 , wherein the daily dosage of the CXCR1 and/or CXCR2 inhibitor is between 1 mg and 100 mg.

18. The method of claim 1 , wherein the subject has been determined to have a value of glomerular filtration rate (GFR) above 60 ml/min/1.73 m 2 .

19. A method of preventing the onset of diabetic nephropathy or the progression of diabetic nephropathy (DN) in a subject in need thereof comprising administering a CXCR1 and/or CXCR2 inhibitor to the subject who has been diagnosed with diabetes and has been determined to have a urinary level of IL8 higher than 2.41 pg/ml.

20. A method of preventing the onset of diabetic nephropathy or the progression of diabetic nephropathy (DN) in a subject in need thereof comprising administering a CXCR1 and/or CXCR2 inhibitor to the subject who has been diagnosed with diabetes and has been determined to have a value of glomerular filtration rate (GFR) above 60 ml/min/1.73 m 2 .

Assignees

• Childrens Medical Ct Corp
• Dompe Farm Spa

Inventors

• Fiorina Paolo
• Bassi Roberto
• Vergani Andrea
• Allegretti Marcello

Classifications

• G01N33/68

  involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)} · CPC title

• A61K31/426

  1,3-Thiazoles · CPC title

• A61P13/12

  of the kidneys · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title